Qingdao Vland Biotech Performance dei guadagni passati
Il passato criteri di controllo 0/6
Qingdao Vland Biotech's earnings have been declining at an average annual rate of -6.3%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 8.1% per year. Qingdao Vland Biotech's return on equity is 5.2%, and it has net margins of 5.2%.
Informazioni chiave
-6.3%
Tasso di crescita degli utili
-10.1%
Tasso di crescita dell'EPS
| Biotechs Crescita del settore | 11.3% |
| Tasso di crescita dei ricavi | 8.1% |
| Rendimento del capitale proprio | 5.2% |
| Margine netto | 5.2% |
| Ultimo aggiornamento sui guadagni | 30 Sep 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Some Qingdao Vland Biotech INC. (SHSE:603739) Shareholders Look For Exit As Shares Take 27% Pounding
Sep 05
Qingdao Vland Biotech INC.'s (SHSE:603739) Popularity With Investors Under Threat As Stock Sinks 26%
Jun 07Investors Shouldn't Be Too Comfortable With Qingdao Vland Biotech's (SHSE:603739) Earnings
May 06Qingdao Vland Biotech INC. (SHSE:603739) Might Not Be As Mispriced As It Looks
Apr 16Ripartizione dei ricavi e delle spese
Come Qingdao Vland Biotech guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 30 Sep 24 | 1,265 | 66 | 341 | 111 |
| 30 Jun 24 | 1,264 | 79 | 338 | 114 |
| 31 Mar 24 | 1,253 | 83 | 340 | 115 |
| 31 Dec 23 | 1,199 | 81 | 327 | 111 |
| 30 Sep 23 | 1,213 | 71 | 324 | 111 |
| 30 Jun 23 | 1,175 | 64 | 321 | 104 |
| 31 Mar 23 | 1,140 | 62 | 308 | 101 |
| 31 Dec 22 | 1,163 | 70 | 309 | 102 |
| 30 Sep 22 | 1,148 | 92 | 300 | 99 |
| 30 Jun 22 | 1,134 | 109 | 288 | 104 |
| 31 Mar 22 | 1,141 | 122 | 292 | 103 |
| 31 Dec 21 | 1,151 | 133 | 291 | 101 |
| 30 Sep 21 | 1,100 | 130 | 275 | 96 |
| 30 Jun 21 | 1,078 | 126 | 281 | 91 |
| 31 Mar 21 | 1,030 | 116 | 276 | 86 |
| 31 Dec 20 | 960 | 109 | 264 | 80 |
| 30 Sep 20 | 922 | 103 | 282 | 74 |
| 30 Jun 20 | 884 | 89 | 278 | 75 |
| 31 Mar 20 | 870 | 89 | 272 | 74 |
| 31 Dec 19 | 847 | 78 | 269 | 75 |
| 30 Sep 19 | 840 | 79 | 253 | 78 |
| 30 Jun 19 | 824 | 81 | 235 | 73 |
| 31 Mar 19 | 808 | 84 | 229 | 70 |
| 31 Dec 18 | 814 | 83 | 227 | 70 |
| 30 Sep 18 | 805 | 86 | 396 | 121 |
| 31 Dec 17 | 799 | 86 | 233 | 71 |
| 31 Dec 16 | 781 | 83 | 240 | 77 |
| 31 Dec 15 | 752 | 70 | 227 | 83 |
| 31 Dec 14 | 728 | 53 | 336 | 0 |
Guadagni di qualità: 603739 has a large one-off gain of CN¥24.5M impacting its last 12 months of financial results to 30th September, 2024.
Margine di profitto in crescita: 603739's current net profit margins (5.2%) are lower than last year (5.8%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: 603739's earnings have declined by 6.3% per year over the past 5 years.
Accelerare la crescita: 603739's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Guadagni vs Settore: 603739 had negative earnings growth (-6.7%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Rendimento del capitale proprio
ROE elevato: 603739's Return on Equity (5.2%) is considered low.